Hematology & Oncology Headlines

Life-Gained-Based Selection Could Maximize the Benefits of Lung Cancer Screening

Novel Agent Tislelizumab Extends Survival in Lung Cancer: Interim Phase III Report

The novel agent tislelizumab improved progression-free survival (PFS; primary endpoint) in the firstline setting in patients with squamous non-small cell lung cancer (NSCLC), according to interim data from a randomized, phase III study. The open-label,...

Journal Reading List

2019 ASCO Annual Meeting

Conversations with Experts